CA
AMRI

Cetera Advisors’s Albany Molecular Research Inc AMRI Stock Holding History

Cetera Advisors’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-13,255
Closed -$172K – 532
2013
Q3 		$172K Buy
+13,255
New +$163K 0.03% 414

Other funds holding AMRI

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Cetera Advisors's AMRI Position: Q4 2013 in Review

Cetera Advisors sold out of Albany Molecular Research Inc (AMRI) in Q4 2013, closing a stake of 13,255 shares — an estimated $172K sold.

Cetera Advisors first reported a position in AMRI in Q3 2013 and held it in 1 quarter. The position peaked at $172K in Q3 2013. 118 funds tracked by Wall St. Rank hold AMRI as of Q4 2013.

  • Cetera Advisors reported no remaining Albany Molecular Research Inc position as of Q4 2013 after selling out during the quarter.
  • Cetera Advisors sold 13,255 Albany Molecular Research Inc shares in Q4 2013, an estimated $172K.
  • Cetera Advisors first reported a position in Albany Molecular Research Inc in Q3 2013 and held it in 1 quarter.
  • Cetera Advisors's Albany Molecular Research Inc position peaked at $172K in Q3 2013.
  • 118 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q4 2013.

Based on Cetera Advisors's 13F filing for Q4 2013, filed 12 Feb 2014.